Collectively, these findings establish that CTHRC1+ CAFs drive poor outcomes by creating an immunosuppressive, pro-invasive niche and directly promoting tumor aggressiveness via a CTHRC1-WNT5A-MSLN signaling axis. The gene discussed is CTHRC1; the disease is neoplasm.